Sun Pharma-owned subsidiary to acquire Canada's Aquinox Pharma for $8.2 mn

Indian company says no approvals are required for the acquisition and it is likely to be completed by July 31

Sun Pharma
Taro Pharmaceutical is a US-based subsidiary of Sun Pharmaceutical.
IANS
1 min read Last Updated : Jul 29 2020 | 1:26 PM IST

Sun Pharmaceutical Industries on Wednesday said that a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd will acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 million.

Taro Pharmaceutical is a US-based subsidiary of Sun Pharmaceutical.

"One of the wholly owned subsidiaries of our subsidiary company, Taro Pharmaceutical Industries Ltd., has agreed to acquire by way of purchase of all outstanding shares of Aquinox Pharmaceuticals (Canada) Inc.," Sun Pharma said in a regulatory filing.

Aquinox Pharmaceuticals is a corporation organised and existing under the laws of the Province of British Columbia that carries on the business of research and development of pharmaceutical products for purposes of their commercialization, it added.

The subsidiary of Taro Pharmaceutical will acquire 100 per cent stake in the company.

The company said that no approvals are required for the acquisition and it is likely to be completed by July 31.

Sun Pharma shares surged on Wednesday on the back of the announcement. At 10.56 a.m., its shares on the BSE were trading at Rs 491.05, higher by Rs 8.55 or 1.77 per cent from its previous close.

 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Sun Pharmaacquisitionshares

Next Story